Back to News & Events

Long Island Bioscience Hub Announces Additional Funded Projects

Third round of grants awarded for the development of commercially promising biomedical innovations

The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the third round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $550,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Eighteen months after its establishment, the LIBH has already awarded more than $2M to faculty innovators.

The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.

A wide range of disciplines are represented in the project awards this cycle including radiology, quantitative biology, biomedical engineering, chemistry, neurosurgery and cancer research. Nine Feasibility awards and one Proof of Concepts award have been funded this cycle. Projects awarded funding in this round include the development of radiotracers for use with PET scans to detect bacterial infections, specifically infective endocarditis (IE); a non-immune-based drug targeting amyloid ß-protein (Aß) for the treatment of mild Alzheimer’s disease; DNA nano-carrier platform technology for targeted anti-thrombotic drug delivery in prosthetic heart valve and mechanical circulatory support patients; A medical device utilizing electrical and software engineering in order to detect congenital heart disease in newborn children, and profiling the human immune system through machine learning and bioinformatics. The full list of funded projects can be found on the LIBH webpage.

“The latest announcement of funded project for the LIBH demonstrates the volume of innovation housed within partner institutes that is primed to be moved out of the academic lab and into the commercial sector in order to help patients” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “It is exciting to witness our region’s innovators contemplating their research in ways they hadn’t before, and to see the vibrancy of the bioscience cluster on Long Island growing with each new project proposed.”

“Putting CSHL scientists together with HUB biotech entrepreneurs and industry reviewers is key to the successful translation of early stage ideas resulting from the basic research of Dr. Lingbo Zhang and Mickey Atwal, said Teri Willey, CSHL Vice President Business Development and Technology Transfer. “Zhang’s genetic research on myelodysplastic syndrome will be complimented by experience in medicinal chemistry. Similarly, Atwal’s work on developing therapeutics using physics and math to profile to the immune system will benefit from industry reviewers to guide it toward patient benefit.”

“The success of the Long Island Bioscience Hub demonstrates the value of creative partnerships in bringing medical solutions that help address patients’ needs from the research lab to the doctor’s office and the medical clinic. We are proud to be part of the Bioscience Hub’s success,” said Kevin J. Tracey, M.D., President and CEO of the Feinstein Institute.

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Download a PDF of the press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4906
                    [post_author] => 4
                    [post_date] => 2025-07-17 10:27:09
                    [post_date_gmt] => 2025-07-17 14:27:09
                    [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4929 [post_author] => 4 [post_date] => 2026-02-16 13:07:36 [post_date_gmt] => 2026-02-16 18:07:36 [post_content] =>

In early February, we welcomed leadership from Empire State Development (ESD), including its Division of Science, Technology and Innovation (NYSTAR) and New York Ventures, for a two-day visit focused on applied research, industry collaboration and economic development across New York State.

The visit spotlighted key teams throughout Stony Brook University, including the Center’s role in driving innovation through supporting hundreds of patents, licenses, and commercialization efforts to help translate breakthrough discoveries into real‑world medical and biotechnology applications. As our very own Clinton Rubin remarked, "We are excited by NYS’s commitment to harnessing Stony Brook’s research enterprise for economic impact, and building the life sciences innovation and entrepreneurship ecosystem here on campus, on Long Island and in our State.”

We’re excited to share more soon about how our Center is bringing its vision to life by accelerating the path from academic research to marketplace solutions.

[post_title] => NYSTAR Visits SBU [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nystar-visits-sbu [to_ping] => [pinged] => [post_modified] => 2026-03-09 13:25:51 [post_modified_gmt] => 2026-03-09 17:25:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4929 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2439 [post_author] => 4 [post_date] => 2016-10-27 00:01:04 [post_date_gmt] => 2016-10-27 00:01:04 [post_content] => DepYMed Inc. has announced the completion of a Series ‘A’ Round of funding with TopSpin Fund, L.P. for a total of $2 million. At closing, $1 million was received by Depymed, and another $1 million will be provided pending the achievement of specific development milestones. DepYmed, Inc., headed by a Center for Biotechnology BioEntrepreneur-in-Residence Andreas G. Grill, is a pharmaceutical company focused on phosphatase inhibition for multiple therapeutic applications. The company is currently conducting a phase 1 clinical trial of its lead compound, MSI-1436C (Trodusquemine), as a therapeutic candidate for HER2-positive breast cancer. DepYMed was founded through a joint venture between Ohr Pharmaceutical, Inc. and Cold Spring Harbor Laboratory. Read more about the financing here. [post_title] => DepYmed Announces $2 Million Series A [post_excerpt] => DepYMed, a joint venture between Ohr Pharmaceutical, Inc. and Cold Spring Harbor Laboratory, has announced the completion of a Series ‘A’ Round of funding with TopSpin Fund, L.P. for a total of $2 million. [post_status] => publish [comment_status] => closed [ping_status] => open [post_password] => [post_name] => depymed-announces-2-million-series-a [to_ping] => [pinged] => [post_modified] => 2016-12-22 17:27:57 [post_modified_gmt] => 2016-12-22 17:27:57 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2439 [menu_order] => 162 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4947 [post_author] => 4 [post_date] => 2026-02-17 15:36:00 [post_date_gmt] => 2026-02-17 20:36:00 [post_content] =>

The Center for Biotechnology was thrilled to help Stony Brook University’s Office for Research and Innovation (OR&I) organize their second Wolf Den event on February 12, which featured three CFB Affiliated biotechnology entrepreneurs: Eve McDavid, CEO and founder of Mission-Driven Tech, Raza Hassan, CTO and co-founder of IAMBIC and Christopher Ashdown, CEO and co-founder of Lahara Bio

Attendees heard from each of the featured innovators about various topics they have faced while launching and building their ventures. The speakers were also able to highlight how they have worked with and access the resources of Stony Brook University with support from the Center for Biotechnology.

The goal of the event is to help build the innovation and entrepreneurial community not only at Stony Brook University but in the region as well. Read the full write up of the event on SBU News.

[post_title] => CFB Affiliated Entrepreneurs Featured at SBU’s Wolf Den Event [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-affiliated-entrepreneurs-featured-at-sbus-wolf-den-event [to_ping] => [pinged] => [post_modified] => 2026-03-10 15:44:09 [post_modified_gmt] => 2026-03-10 19:44:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4947 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4906 [post_author] => 4 [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 [post_content] =>

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 282 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology

More Information

NYSTAR Visits SBU

More Information

DepYmed Announces $2 Million Series A

More Information

CFB Affiliated Entrepreneurs Featured at SBU’s Wolf Den Event

More Information